VARGATEF® (nintedanib) is a triple angiokinase inhibitor approved as a combination treatment for 2nd line NSCLC patients with distinct types of adenocarcinoma.
http://www.vargatef.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
1 seconds
Boehringer Ingelheim International GmbH
3460-02-06 Corporate Department Trademarks
Binger●●●●●●se 173
Ing●●●eim , D - 55216
DE
View this contact
Boehringer Ingelheim GmbH
3344-EG-04 I*Net Solution Center
Abteilung I●●●●●●●●●●●erarbeitung
Ing●●●eim , Rheinland-Pfalz, D-55216
DE
View this contact
CSC Corporate Domains
Domain Registrar
PO ●●●597
Yar●●●uth , NS, B5A 4B4
CA
View this contact
BUY YOUR DOMAIN
18
YEARS
0
MONTHS
23
DAYS
CSC CORPORATE DOMAINS, INC.
WHOIS : whois.corporatedomains.com
REFERRED : http://www.cscglobal.com
PAGES IN
THIS WEBSITE
15
SSL
EXTERNAL LINKS
5
SITE IP
94.100.253.195
LOAD TIME
0.958 sec
SCORE
6.2
VARGATEF® (nintedanib) | A triple angiokinase inhibitor | vargatef.com Reviews
https://vargatef.com
VARGATEF® (nintedanib) is a triple angiokinase inhibitor approved as a combination treatment for 2nd line NSCLC patients with distinct types of adenocarcinoma.
vargatef.com
VARGATEF® indication & usage | nintedanib plus docetaxel
http://www.vargatef.com/about_vargatef/indication_and_usage.html
LUME-Lung 1 trial design. LUME-Lung 1 trial: efficacy. PFS in ITT Population. OS in patients with adenocarcinoma histology. Safety and quality of life. This webpage is intended for healthcare professionals within the European Union. 04 November 2015. LUME-Lung 1 trial design. Is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
VARGATEF® Dosage with docetaxel | Dosing Regimen
http://www.vargatef.com/managing_treatment/dosing_regimen.html
LUME-Lung 1 trial design. LUME-Lung 1 trial: efficacy. PFS in ITT Population. OS in patients with adenocarcinoma histology. Safety and quality of life. This webpage is intended for healthcare professionals within the European Union. 05 November 2015. Twice daily oral VARGATEF. Has a well-defined and simple dosing regimen. Patients may continue therapy with VARGATEF. After discontinuation of docetaxel for as long as clinical benefit is observed or until unacceptable toxicity occurs.
VARGATEF® Safety and Adverse Events | LUME Lung 1
http://www.vargatef.com/safety_and_qol.html
LUME-Lung 1 trial design. LUME-Lung 1 trial: efficacy. PFS in ITT Population. OS in patients with adenocarcinoma histology. Safety and quality of life. This webpage is intended for healthcare professionals within the European Union. 05 November 2015. In LUME-Lung 1, adverse events. Plus docetaxel were generally manageable. Docetaxel had a comparable discontinuation rate due to AEs to docetaxel alone (20.9% vs 17.7%, respectively). WBC= White Blood Cell. Reck M et al. Lancet Oncol 2014;15:143 55.
VARGATEF® Overall Survival in Adenocarcinoma Patients
http://www.vargatef.com/efficacy_results/os_in_2nd-line_adenocarcinomapatients.html
LUME-Lung 1 trial design. LUME-Lung 1 trial: efficacy. PFS in ITT Population. OS in patients with adenocarcinoma histology. Safety and quality of life. This webpage is intended for healthcare professionals within the European Union. 04 November 2015. LUME-Lung 1 trial: efficacy. PFS in ITT Population. OS in patients with adenocarcinoma histology. LUME-Lung 1 trial: efficacy. For the subgroup of patients with an adenocarcinoma histology, VARGATEF. Overall survival (OS) was the key secondary endpoint.
VARGATEF® Safety and Adverse Events | LUME Lung 1
http://www.vargatef.com/safety_and_qol/adverse_events.html
LUME-Lung 1 trial design. LUME-Lung 1 trial: efficacy. PFS in ITT Population. OS in patients with adenocarcinoma histology. Safety and quality of life. This webpage is intended for healthcare professionals within the European Union. 05 November 2015. In LUME-Lung 1, adverse events. Plus docetaxel were generally manageable. Docetaxel had a comparable discontinuation rate due to AEs to docetaxel alone (20.9% vs 17.7%, respectively). WBC= White Blood Cell. Reck M et al. Lancet Oncol 2014;15:143 55.
TOTAL PAGES IN THIS WEBSITE
15
LUX-Lung 3 Clinical Trial | GIOTRIF® (afatinib)
https://www.giotrif.com/healthcare_professionals/first_line_efficacy_and_safety/pfs.html
Skip to main content. GIOTRIF (afatinib) as monotherapy is indicated for the treatment of: Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. For more information please see the EU Summary of Product Characteristics. See countries where GIOTRIF. 1st Line EGFR M. Demonstrated su...
EGFR Mutations & Biomarker Testing | GIOTRIF® (afatinib)
https://www.giotrif.com/healthcare_professionals/egfr_testing/incidence.html
Skip to main content. GIOTRIF (afatinib) as monotherapy is indicated for the treatment of: Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. For more information please see the EU Summary of Product Characteristics. See countries where GIOTRIF. 1st Line EGFR M. Based on multip...
EGFR Mutations & Biomarker Testing | GIOTRIF® (afatinib)
https://www.giotrif.com/healthcare_professionals/egfr_testing/Guidelines-on-Testing.html
Skip to main content. GIOTRIF (afatinib) as monotherapy is indicated for the treatment of: Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. For more information please see the EU Summary of Product Characteristics. See countries where GIOTRIF. 1st Line EGFR M. Based on multip...
LUX-Lung 3 Clinical Trial | GIOTRIF® (afatinib)
https://www.giotrif.com/healthcare_professionals/first_line_efficacy_and_safety/os.html
Skip to main content. GIOTRIF (afatinib) as monotherapy is indicated for the treatment of: Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. For more information please see the EU Summary of Product Characteristics. See countries where GIOTRIF. 1st Line EGFR M. Demonstrated su...
TOTAL LINKS TO THIS WEBSITE
5
Varga Tamás
Varga Tanya Hotel
Varga Tanya Hotel, Konferencia és Szabadidő Központ. Varga Tanya Hotel Konferencia és Szabadidő Központ. A Varga Tanya Hotel Konferencia és Szabadidő Központ Magyarország szívében, a Kiskunsági Nemzeti Park mellett helyezkedik el. Budapesttől 1-1,5 órányira, az M5-ös autópályától 16 km távolságra fekszik. A jó közérzethez, kényeztetéshez járul a különleges berendezés, a hangulatos világítás. Hagyomány és modernitás harmonikus találkozása". A mai stresszes rohanó világunkban néha elengedhetetlen, hogy kis...
Varga Tanya
Vítajte na stránkach reštaurácie a vinárne Varga Tanya. Agroturistické centrum Oborín 076 75, okres Michalovce, Slovenská Republika. Tel: 421 917 462 777 e-mail: vargatanya@centrum.sk www.vargatanya.sk.
Varga tanya
Kezdőlap
Tapéták készletről már 800Ft-tól. Több mint 350 féle tapéta készletről! Bordűrök 3cm-től 17cm-ig már 300Ft-tól. 7636 Pécs, Illyés Gy. u. 12. 2013 - Powered by Beautiful-Templates.com.
VARGATEF® (nintedanib) | A triple angiokinase inhibitor
LUME-Lung 1 trial design. PFS in ITT Population. OS in patients with adenocarcinoma histology. Safety and quality of life. This webpage is intended for healthcare professionals within the European Union. 04 August 2015. A triple angiokinase inhibitor approved in combination with docetaxel for the treatment of patients with distinct types of adenocarcinoma of the lung after first-line chemotherapy. In the LUME-Lung 1 trial, VARGATEF. When added to docetaxel, demonstrated over one year (12.6 months) me...
VargaTek Systems - Coming Soon
Online Training Tool | Digital Education – Vargatex
Contact: 082 656 9430 / 011 083 8815. Products & Services. Digital Information and Content Distribution Specialists! Vargatex is an innovative social enterprise that develops solutions, designed specifically for African businesses. Our expertise includes software development, ICT hardware sourcing and deployment, project management and ICT consulting with a focus for knowledge driven institutions and businesses. We are an organization that looks at tackling social problems with business solutions. The fr...
Vargath's blog - El Vargath - Skyrock.com
Lachez juste vos com sur mon blog! POur moi le sport est essentiel pour la vie et bien se sentir dans sa peau! Vive les jeux de role et els vacanaces! Les cours sa puent et sa me soule de plus en plus! 01/09/2006 at 3:29 AM. 29/03/2007 at 8:21 AM. Saturation.Depuis quelques mois des. Subscribe to my blog! ATTENTION/ /Tout skyblog ne contenant pas cet article sera supprimé pour alléger le système. Merci de votre compréhension. Toute l'équipe de skyblog. Posted on Tuesday, 13 March 2007 at 1:15 PM. Posted ...
Vargatherm Kft.
Fő tevékenységi körünk a víz-, gáz-, fűtés-, klíma-, légtechnikai rendszerek tervezése, kivitelezése, valamint épületgépészeti anyagok, berendezések kereskedelme. Fizetési módok. A VARGATHERM Szakáruházban bankkártyás fizetési lehetőség biztosított. Aacute;ruhitel vehető igénybe. Üdvözöljük a VARGATHERM Kft. honlapján! Központi telephelyünkön egy 500 négyzetméteres szakáruházat működtetünk, ahol több mint 10000-féle árucikket forgalm...Gázkészülék szerviz:. 36 (30) 438 8618. Munkáinkból: Megújuló energiá...
Vargathrone - DeviantArt
Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')" class="mi". Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')". Join DeviantArt for FREE. Forgot Password or Username? Deviant for 4 Years. This deviant's full pageview. April 20, 1994. Last Visit: 1 day ago. By moving, adding and personalizing widgets. Tiina T&...
